Terms: = Lymphoma AND ZFHX3, ATBT, 463, ENSG00000140836, Q15911 AND Treatment
47 results:
1. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Chantrathammachart P; Puavilai T; Chuncharunee S
Hematology; 2022 Dec; 27(1):1237-1245. PubMed ID: 36413354
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and biological prognostic factors in follicular lymphoma patients.
Jóna Á; Kenyeres A; Barna S; Illés Á; Simon Z
PLoS One; 2022; 17(8):e0272787. PubMed ID: 35925993
[TBL] [Abstract] [Full Text] [Related]
3. treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting.
Kumar AJ; Chao CR; Rodday AM; Chang H; Xu L; Evens AM; Parsons SK
Leuk Lymphoma; 2022 May; 63(5):1119-1126. PubMed ID: 34886751
[TBL] [Abstract] [Full Text] [Related]
4. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Sekhri R; Sadjadian P; Becker T; Kolatzki V; Huenerbein K; Meixner R; Marchi H; Wallmann R; Fuchs C; Griesshammer M; Wille K
Ann Hematol; 2021 Nov; 100(11):2707-2716. PubMed ID: 34462786
[TBL] [Abstract] [Full Text] [Related]
5. TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
Kuijvenhoven MA; Wilhelm AJ; Meijer E; Janssen JJWM; Swart EL
Eur J Haematol; 2021 Sep; 107(3):364-369. PubMed ID: 34114691
[TBL] [Abstract] [Full Text] [Related]
6. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):598-606. PubMed ID: 33866947
[TBL] [Abstract] [Full Text] [Related]
7. [The prognostic impact of diabetic mellitus and hyperglycemia during DLBCL treatment on patients with diffuse large B-cell lymphoma].
Hu Y; Xu YJ; Li MZ; Lan YX; Mao L; Ning QY; Xu W; Yang HL; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):151-157. PubMed ID: 33858047
[No Abstract] [Full Text] [Related]
8. Evolution of Systemic treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer.
Stock-Martineau S; Laurie K; McKinnon M; Zhang T; Wheatley-Price P
Curr Oncol; 2020 Dec; 28(1):60-68. PubMed ID: 33704175
[TBL] [Abstract] [Full Text] [Related]
9. [Analysis of clinical characteristics, treatment and survival of elderly patients with large diffuse B-cell lymphoma].
Li CY; Yang P; Dong F; Tian L; Wan W; Zhao W; Li QH; Pang M; Zhen JF; Jing HM
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3296-3302. PubMed ID: 33202490
[No Abstract] [Full Text] [Related]
10. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.
Autry RJ; Paugh SW; Carter R; Shi L; Liu J; Ferguson DC; Lau CE; Bonten EJ; Yang W; McCorkle JR; Beard JA; Panetta JC; Diedrich JD; Crews KR; Pei D; Coke CJ; Natarajan S; Khatamian A; Karol SE; Lopez-Lopez E; Diouf B; Smith C; Gocho Y; Hagiwara K; Roberts KG; Pounds S; Kornblau SM; Stock W; Paietta EM; Litzow MR; Inaba H; Mullighan CG; Jeha S; Pui CH; Cheng C; Savic D; Yu J; Gawad C; Relling MV; Yang JJ; Evans WE
Nat Cancer; 2020 Mar; 1(3):329-344. PubMed ID: 32885175
[TBL] [Abstract] [Full Text] [Related]
11. The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG.
Dalle JH; Balduzzi A; Bader P; Pieczonka A; Yaniv I; Lankester A; Bierings M; Yesilipek A; Sedlacek P; Ifversen M; Svec P; Toporski J; Gungor T; Wachowiak J; Glogova E; Poetschger U; Peters C
Bone Marrow Transplant; 2021 Jan; 56(1):257-266. PubMed ID: 32753706
[TBL] [Abstract] [Full Text] [Related]
12. Imaging Surveillance of Limited-stage Classic Hodgkin lymphoma Patients After PET-CT-documented First Remission.
Glober G; Gunther J; Fang P; Milgrom S; Korivi BR; Jensen CT; Wagner-Bartak NA; Ahmed S; Lee HJ; Nair R; Steiner R; Parmar S; Iyer S; Westin J; Fayad L; Rodriguez MA; Neelapu S; Nastoupil L; Flowers CR; Dabaja BS; Pinnix CC
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):533-541. PubMed ID: 32291233
[TBL] [Abstract] [Full Text] [Related]
13. Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients.
Elsayad K; Reinartz G; Oertel M; Rehn S; Eismann J; Scobioala S; Berssenbrügge H; Eter N; Weishaupt C; Schmidt HH; Friedrichs B; Grünewald I; Hartmann W; Lenz G; Wardelmann E; Willich N; Eich HT
Strahlenther Onkol; 2020 Feb; 196(2):117-125. PubMed ID: 31732783
[TBL] [Abstract] [Full Text] [Related]
14. [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].
Chen M; Yang JL; Zhao S; Liu WP; Li GD; Ye YX; Yan JQ; Zhang WY
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):920-925. PubMed ID: 30522172
[No Abstract] [Full Text] [Related]
15. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort.
Gibson TM; Mostoufi-Moab S; Stratton KL; Leisenring WM; Barnea D; Chow EJ; Donaldson SS; Howell RM; Hudson MM; Mahajan A; Nathan PC; Ness KK; Sklar CA; Tonorezos ES; Weldon CB; Wells EM; Yasui Y; Armstrong GT; Robison LL; Oeffinger KC
Lancet Oncol; 2018 Dec; 19(12):1590-1601. PubMed ID: 30416076
[TBL] [Abstract] [Full Text] [Related]
16. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.
Schiller GJ; Damon LE; Coutre SE; Hsu P; Bhat G; Douer D
J Adolesc Young Adult Oncol; 2018 Oct; 7(5):546-552. PubMed ID: 30239252
[TBL] [Abstract] [Full Text] [Related]
17. Characteristics, outcome and treatments with cranial pachymeningitis: A multicenter French retrospective study of 60 patients.
Mekinian A; Maisonobe L; Boukari L; Melenotte C; Terrier B; Ayrignac X; Schleinitz N; Sène D; Hamidou M; Konaté A; Guilpain P; Abisror N; Ghrenassia E; Lachenal F; Cevallos R; Roos-Weil R; Du LTH; Lhote F; Larroche C; Bergmann JF; Humbert S; Fraison JB; Piette JC; Guillevin L; Dhote R; Amoura Z; Haroche J; Fain O
Medicine (Baltimore); 2018 Jul; 97(30):e11413. PubMed ID: 30045263
[TBL] [Abstract] [Full Text] [Related]
18. An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas.
Abdel-Rahman O
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1071-1076. PubMed ID: 28889760
[TBL] [Abstract] [Full Text] [Related]
19. Risk Factors and Outcomes for Patients With Follicular lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
Sarkozy C; Trneny M; Xerri L; Wickham N; Feugier P; Leppa S; Brice P; Soubeyran P; Gomes Da Silva M; Mounier C; Offner F; Dupuis J; Caballero D; Canioni D; Paula M; Delarue R; Zachee P; Seymour J; Salles G; Tilly H
J Clin Oncol; 2016 Aug; 34(22):2575-82. PubMed ID: 27298402
[TBL] [Abstract] [Full Text] [Related]
20. The effect of chemotherapy-induced anemia on dose reduction and dose delay.
Family L; Xu L; Xu H; Cannavale K; Sattayapiwat O; Page JH; Bohac C; Chao C
Support Care Cancer; 2016 Oct; 24(10):4263-71. PubMed ID: 27167627
[TBL] [Abstract] [Full Text] [Related]
[Next]
